AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31269910 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytic HLA-DR (mHLA-DR) expression, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-alpha), lipopolysaccharide-binding protein (LBP)
Number of subjects: 486
Study 31269910 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL-6) levels on day 1
Number of subjects: 486
Study 31269910 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke-associated pneumonia (SAP)
Number of subjects: 486
Study 31269910 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytic HLA-DR (mHLA-DR) expression
Number of subjects: 486
Study 31269910 — intervention group
Group type: EXPERIMENTAL
Intervention: National Institute of Health Stroke Scale (NIHSS) score
Number of subjects: 486
Study 31269923 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete immunological profile using classical descriptive immune phenotyping and TruCulture®
Number of subjects: 630
Study 31269978 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 160
Study 31269978 — intervention group
Group type: COMPARATOR
Intervention: Ambulatory phlebectomies
Number of subjects: 160
Study 31270080 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPN2-deleted T-ALL
Number of subjects: 430
Study 31270080 — intervention group
Group type: EXPERIMENTAL
Intervention: PTPN2-deleted pediatric cases
Number of subjects: 430
Study 31270080 — intervention group
Group type: COMPARATOR
Intervention: PTPN2-deleted adult cases
Number of subjects: 430
Study 31270103 — intervention group
Group type: EXPERIMENTAL
Intervention: DARA-MD 1200 mg
Number of subjects: 53
Study 31270103 — intervention group
Group type: EXPERIMENTAL
Intervention: DARA-MD 1800 mg
Number of subjects: 53
Study 31270178 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 96
Study 31270178 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-s STS test
Number of subjects: 96
Study 31270178 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 96
Study 31270738 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0
Study 31270738 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel risk score model for primary prevention of SCD
Number of subjects: 0
Study 31270738 — intervention group
Group type: EXPERIMENTAL
Intervention: Current ICD indications according to international Consensus Statement
Number of subjects: 0
Study 31270774 — intervention group
Group type: EXPERIMENTAL
Intervention: Active therapy
Number of subjects: 90
Study 31270774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 31271463 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal tenofovir treatment during the third trimester
Number of subjects: 201
Study 31271463 — intervention group
Group type: COMPARATOR
Intervention: Control (no tenofovir treatment)
Number of subjects: 201
Study 31272391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 20
Study 31272402 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWHs)
Number of subjects: 2381
Study 31272487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based reminders
Number of subjects: 400
Study 31272487 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based reminders and incentives (conditional financial transfers)
Number of subjects: 400
Study 31272487 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no reminders or incentives)
Number of subjects: 400
Study 31272485 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic esophagectomy with at least 2-field lymphadenectomy
Number of subjects: 5000
Study 31272548 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic Valve Replacement (AVR)
Number of subjects: 23528
Study 31272934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen apposing metal stents (LAMS)
Number of subjects: 192
Study 31273088 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag, an oral thrombopoietin-mimetic, dosage and duration not specified
Number of subjects: 24
Study 31273510 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 20
Study 31273510 — intervention group
Group type: COMPARATOR
Intervention: Normal persons (control group)
Number of subjects: 20
Study 31273686 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine + lopinavir/ritonavir (TDF/FTC LPV/r; arm A)
Number of subjects: 0
Study 31273686 — intervention group
Group type: COMPARATOR
Intervention: abacavir + didanosine + lopinavir/ritonavir (arm B)
Number of subjects: 0
Study 31273686 — intervention group
Group type: COMPARATOR
Intervention: tenofovir/emtricitabine + darunavir/ritonavir (arm C)
Number of subjects: 0
Study 31273942 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline seropositive women
Number of subjects: 2687
Study 31274114 — intervention group
Group type: EXPERIMENTAL
Intervention: PARTNER intervention (4-session motivational interviewing-based intervention with video-based communication training)
Number of subjects: 240
Study 31274114 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched psychoeducation control arm
Number of subjects: 240
Study 31274114 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers for drug use
Number of subjects: 240
Study 31274114 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers for sexual HIV transmission risk
Number of subjects: 240
Study 31274114 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological markers for PrEP adherence
Number of subjects: 240
Study 31274544 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR SS genotype (rs4795541) in Cohort A
Number of subjects: 2773
Study 31274544 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR SS genotype (rs4795541) in Cohort B
Number of subjects: 2773
Study 31274544 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex in Cohort A
Number of subjects: 2773
Study 31274544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking status in Cohort A
Number of subjects: 2773
Study 31274544 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient age in Cohort A
Number of subjects: 2773
Study 31275098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension
Number of subjects: 0
Study 31275098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sleep extension)
Number of subjects: 0
Study 31275206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational integration programs for mentally burdened emerging adults
Number of subjects: 0
Study 31275432 — intervention group
Group type: EXPERIMENTAL
Intervention: Early coronary intervention
Number of subjects: 162
Study 31275432 — intervention group
Group type: COMPARATOR
Intervention: Delayed coronary intervention
Number of subjects: 162
Study 31276005 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment for ATR
Number of subjects: 34
Study 31276156 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 8
Study 31276163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg) IV every 2 weeks
Number of subjects: 10
Study 31277626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined respiratory support (CRS) using high frequency jet ventilation (HFJV) and small volume mechanical ventilation (SVMV)
Number of subjects: 38
Study 31277626 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia with mechanical ventilation (MV)
Number of subjects: 38
Study 31277699 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 (AKT inhibitor)
Number of subjects: 27
Study 31277722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedatives only
Number of subjects: 79
Study 31277722 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids only
Number of subjects: 79
Study 31277722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedatives plus opioids
Number of subjects: 79
Study 31277722 — intervention group
Group type: COMPARATOR
Intervention: No drugs
Number of subjects: 79
Study 31277780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 256
Study 31277780 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose computed tomography (SDCT)
Number of subjects: 256
Study 31277975 — intervention group
Group type: EXPERIMENTAL
Intervention: AVXS-101 (onasemnogene abeparvovec)
Number of subjects: 12
Study 31278103 — intervention group
Group type: COMPARATOR
Intervention: Serum Vitamin B levels
Number of subjects: 1829
Study 31278577 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE
Number of subjects: 100
Study 31278577 — intervention group
Group type: COMPARATOR
Intervention: TE
Number of subjects: 100
Study 31278577 — intervention group
Group type: COMPARATOR
Intervention: pSWE
Number of subjects: 100
Study 31278692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (1200 mg every 2 weeks)
Number of subjects: 644
Study 31278892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive cohort
Number of subjects: 71
Study 31278892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention on renal artery
Number of subjects: 71
Study 31278925 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory strategies
Number of subjects: 168
Study 31278925 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver strategies
Number of subjects: 168
Study 31278925 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education
Number of subjects: 168
Study 31279240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM) patients during spontaneous headache attack (ictal phase)
Number of subjects: 15
Study 31279240 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic migraine (EM) patients during spontaneous headache attack (ictal phase)
Number of subjects: 15
Study 31279240 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC) during spontaneous headache attack (ictal phase)
Number of subjects: 15
Study 31279304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg/day) until disease progression or unacceptable toxicity
Number of subjects: 52
Study 31279304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg/day)
Number of subjects: 52
Study 31279564 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (4 doses during infancy)
Number of subjects: 203
Study 31279564 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-CRM (2 doses at 12/13 and 15 months or 1 dose at 18 months)
Number of subjects: 203
Study 31279564 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM booster dose at 60 months
Number of subjects: 203
Study 31279564 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM (booster dose)
Number of subjects: 203
Study 31279752 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplant
Number of subjects: 17
Study 31279871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg intravenously at weeks 0, 2, and 6, then every 8 weeks thereafter for 26 weeks)
Number of subjects: 101
Study 31280076 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight patients (BMI 25-<30)
Number of subjects: 811
Study 31280076 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI at baseline
Number of subjects: 811
Study 31280076 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during the study
Number of subjects: 811
Study 31280076 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher initial increase in BMI
Number of subjects: 811
Study 31280289 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D machine learning derived models of wall thickness pre-AVR and 1 year post-AVR
Number of subjects: 116
Study 31280289 — intervention group
Group type: COMPARATOR
Intervention: Patients without LVH (16% with normal indexed LV mass, 79% female)
Number of subjects: 116
Study 31280289 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-AVR changes in NT-proBNP
Number of subjects: 116
Study 31280289 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-AVR changes in systolic blood pressure
Number of subjects: 116
Study 31280289 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of NT-proBNP with percentage LV mass regression in males
Number of subjects: 116
Study 31280362 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib (doses ranging from 0.5 to 12 mg, with a highest therapeutic dose of 9 mg daily)
Number of subjects: 187
Study 31280362 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib (concentration-QTc analysis)
Number of subjects: 187
Study 31280390 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT + ADV/TDF
Number of subjects: 31
Study 31280390 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT
Number of subjects: 31
Study 31280918 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Psychology Intervention (PPI)
Number of subjects: 128
Study 31281675 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 0
Study 31281675 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 31282539 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccination (CAM-70) at 6 and 12 months of age
Number of subjects: 283
Study 31282597 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-558, miR-146a, miR-150, miR-124, and miR-143 expression levels
Number of subjects: 150
Study 31282597 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6, TNF-α, and COX-2 levels
Number of subjects: 150
Study 31282597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain thresholds
Number of subjects: 150
Study 31282597 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in miRNA expression
Number of subjects: 150
Study 31282597 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers (IL-6, TNF-α, COX-2)
Number of subjects: 150
Study 31282597 — intervention group
Group type: EXPERIMENTAL
Intervention: Ability to enjoy life and relations with others
Number of subjects: 150
Study 31282758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib plus docetaxel
Number of subjects: 0
Study 31282758 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31283841 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood absence epilepsy (CAE)
Number of subjects: 17
Study 31283841 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 17
Study 31283919 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging subtypes with visual and quantitative features
Number of subjects: 9080
Study 31283919 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative but not visual emphysema
Number of subjects: 9080
Study 31283919 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual but not quantitative emphysema
Number of subjects: 9080
Study 31283919 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE and/or moderate to severe CLE
Number of subjects: 9080
Study 31284072 — intervention group
Group type: EXPERIMENTAL
Intervention: Patent Blue injection into different parts of the pancreas
Number of subjects: 14
Study 31284680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol with active heated humidification at 10 L/min
Number of subjects: 23
Study 31284680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol with active heated humidification at 30 L/min
Number of subjects: 23
Study 31284680 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol with active heated humidification at 50 L/min
Number of subjects: 23
Study 31284680 — intervention group
Group type: COMPARATOR
Intervention: Aerosol with unheated oxygen at 10 L/min
Number of subjects: 23
Study 31284680 — intervention group
Group type: COMPARATOR
Intervention: Aerosol with unheated oxygen at 30 L/min
Number of subjects: 23
Study 31284680 — intervention group
Group type: COMPARATOR
Intervention: Aerosol with unheated oxygen at 50 L/min
Number of subjects: 23
Study 31285068 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD in diabetic patients
Number of subjects: 3045
Study 31285068 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD in nondiabetic patients
Number of subjects: 3045
Study 31285068 — intervention group
Group type: EXPERIMENTAL
Intervention: End-stage renal disease in diabetic patients
Number of subjects: 3045
Study 31285375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stenting (≤14 days)
Number of subjects: 115
Study 31285375 — intervention group
Group type: COMPARATOR
Intervention: Late stenting (>14 days)
Number of subjects: 115
Study 31285522 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (< 8h/day)
Number of subjects: 3211
Study 31285522 — intervention group
Group type: COMPARATOR
Intervention: Long sleep duration (≥ 10h/day)
Number of subjects: 3211
Study 31285780 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 minutes per week of aerobic exercise
Number of subjects: 400
Study 31285780 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 minutes per week of aerobic exercise
Number of subjects: 400
Study 31285780 — intervention group
Group type: COMPARATOR
Intervention: Moderate volume of aerobic exercise (150 min/week)
Number of subjects: 400
Study 31285780 — intervention group
Group type: COMPARATOR
Intervention: High volume of aerobic exercise (300 min/week)
Number of subjects: 400
Study 31285871 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intrapleural chemotherapy (HITHOC)
Number of subjects: 40
Study 31285871 — intervention group
Group type: COMPARATOR
Intervention: Talc pleurodesis (TALC)
Number of subjects: 40
Study 31285876 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublobar resection
Number of subjects: 1579
Study 31285876 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 1579
Study 31286111 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after 10 to 12 years
Number of subjects: 166
Study 31286111 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing stress levels
Number of subjects: 166
Study 31286197 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapopliteal drug-coated balloon angioplasty with the ELUTAX SV DCB
Number of subjects: 164
Study 31286333 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 41
Study 31286884 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Frequency Bioelectrical Impedance Analysis (SFBIA)
Number of subjects: 228
Study 31286884 — intervention group
Group type: COMPARATOR
Intervention: BCRL group (n=22)
Number of subjects: 228
Study 31286890 — intervention group
Group type: EXPERIMENTAL
Intervention: High MP (Mallampati III/IV)
Number of subjects: 584
Study 31286890 — intervention group
Group type: COMPARATOR
Intervention: Low MP (Mallampati I/II)
Number of subjects: 584
Study 31286994 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD-community
Number of subjects: 78
Study 31286994 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD-clinic
Number of subjects: 78
Study 31286994 — intervention group
Group type: COMPARATOR
Intervention: HC
Number of subjects: 78
Study 31286994 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SCD groups
Number of subjects: 78
Study 31287387 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorobutane-enhanced ultrasound (US) combined with conventional B-mode US
Number of subjects: 0
Study 31287387 — intervention group
Group type: COMPARATOR
Intervention: Conventional B-mode ultrasound (US)
Number of subjects: 0
Study 31288365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indocyanine green (5 mg/kg) 24 hours before metastasectomy
Number of subjects: 30
Study 31288365 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR imaging during video-assisted thoracic surgery metastasectomy
Number of subjects: 30
Study 31288565 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT (high-sensitivity troponin T) drawn at baseline and 3 hours
Number of subjects: 499
Study 31288565 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT values below the 99th percentile
Number of subjects: 499
Study 31288863 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil infusion
Number of subjects: 20
Study 31289029 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous T cells engineered to express an affinity-enhanced T-cell receptor (TCR) recognizing NY-ESO-1 and LAGE-1
Number of subjects: 25
Study 31289048 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-related self-care activities (DRSCA)
Number of subjects: 246
Study 31289048 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 246
Study 31289048 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 246
Study 31289075 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Navi© Programme (SN©P) - nurse-led intervention with at least two semistructured consultations and SN©Flyers.
Number of subjects: 140
Study 31289075 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (control).
Number of subjects: 140
Study 31289090 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (PN) during the first 7 postnatal days
Number of subjects: 0
Study 31289090 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 31289238 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injection (100 units)
Number of subjects: 13
Study 31289819 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predictors of ganglion cell/inner plexiform layer atrophy
Number of subjects: 582
Study 31289819 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predictors of sustained loss of 5-letters in low-contrast letter acuity
Number of subjects: 582
Study 31290084 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia protocol (paracetamol, oxycodone, methoxyflurane)
Number of subjects: 200
Study 31290107 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 57
Study 31290107 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 57
Study 31290405 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders only
Number of subjects: 537
Study 31290405 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders plus 150 KES incentive
Number of subjects: 537
Study 31290405 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 537